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Abstract
Background Vascular risk factors (VRFs) may be associated with cognitive decline in early Parkinson’s disease (PD) but 
results are inconclusive. The identification of modifiable risk factors is relevant for prevention and treatment.
Methods Parkinson’s disease (PD) patients of the PACOS cohort who underwent a baseline and follow-up neuropsychologi-
cal evaluation were enrolled in the study. PD with Mild Cognitive Impairment (MCI) and dementia (PDD) were diagnosed 
according to the MDS criteria. A Baseline 1.5 T brain MRI was used to calculate the white matter lesions (WMLs) burden 
using the Wahlund visual scale. Laboratory data, presence of hypertension, diabetes and use of anti-hypertensive drugs were 
collected and the Framingham Risk (FR) score was calculated. VRFs predicting PD-MCI and PDD were evaluated using 
Cox proportional hazard regression model.
Results Out of 139 enrolled patients, 84 (60.4%) were classified as normal cognition (NC) and 55 (39.6%) as MCI at base-
line. At follow-up 28 (33.3%) PD-NC developed MCI and 4 (4.8%) PDD (follow-up time 23.5 ± 10.3 months). Out of 55 
PD-MCI patients at baseline, 14 (25.4%) converted to PDD. At multivariate analysis among PD-NC a systolic blood pres-
sure (SBP) > 140 mmHg was the stronger predictor of MCI (adjHR 4.04; 95% CI 1.41–11.3) while the presence of MCI at 
baseline (adj HR 7.55; 95% CI 1.76–32.3) and a severe WMLs burden (adj HR 2.80; 95% CI 0.86–9.04) were the strongest 
predictors of PDD, even if this latter association has a trend towards significance.
Conclusion Hypertension represents the most important modifiable risk factor for PD-MCI in the PACOS cohort, increasing 
the risk of about four times.
Keywords Parkinson’s disease · Mild cognitive impairment · Hypertension · White matter lesions · Risk factors · 
Epidemiology
Introduction
Cognitive impairment, from mild cognitive impairment 
(MCI) to dementia (PDD), is one of the most common and 
disabling non-motor symptoms of Parkinson’s disease (PD) 
[1].
Despite the efforts to improve the knowledge pertaining 
the pathological bases of cognitive decline in PD, the con-
tribution of vascular pathology is still unclear.
In the general population, some modifiable vascular risk 
factors (VRFs) including hypertension, diabetes, obesity 
and hypercholesterolemia have been associated with cogni-
tive impairment [2, 3]. In particular, it has been suggested 
that VRFs may cause microvascular dysfunction leading to 
chronic hypoperfusion and white matter lesions (WMLs) [4]. 
In particular, VRFs contribute to damage neuronal circuits 
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involved in cognition, including those connecting thalamus, 
basal ganglia, internal capsule and brainstem to the frontal 
lobes [5].
In PD, some studies have associated the co-occurrence 
of VRFs and WMLs with worse motor and cognitive per-
formances, particularly in late-onset PD [6, 7]. Given that 
cognitive impairment represents a frequent condition even 
in de novo PD subjects in early stages [8, 9], the need to 
define whether VRFs represent a modifiable risk factor for 
slowing down or even prevent cognitive decline is urgent. 
Nevertheless, to date only few studies, three cross-sectional 
and three longitudinal, have investigated the effects of VRFs 
on PD-MCI and PDD occurrence according to the Move-
ment Disorder Society (MDS) level II diagnostic criteria for 
PD-MCI [10, 11], reporting inconclusive results [7, 12–16].
This study is part of The PArkinson’s disease COgni-
tive impairment Study (PACOS), an observational study 
involving two Sicilian centers, aimed to assess frequency, 
clinical features and biomarkers associated with MCI in a 
large hospital-based cohort of patients affected by PD [8, 9, 
17–19]. The aim of the present study was to evaluate the role 
of VRFs and WMLs burden as putative risk factors for the 
occurrence of PD-MCI and its progression to PDD.
Materials and methods
Study population
PD patients diagnosed according to the Brain Bank criteria 
[20] who attended the Neurologic Unit of the “Policlinico 
Vittorio Emanuele” in Catania and the Memory and Parkin-
son’s disease Center of the “Policlinico Paolo Giaccone” in 
Palermo, were retrospectively enrolled in the PACOS cohort. 
The population included 659 non-demented PD subjects at 
baseline. All participants underwent a standard neurologi-
cal workup, including a comprehensive neuropsychological 
assessment. Background and methods have been extensively 
reported elsewhere [8, 9].
We retrospectively enrolled all PD patients who under-
went at least two comprehensive neuropsychological evalu-
ation (baseline and follow-up) between 2014 and 2017 
during a period of maximum 48 months (between 12 and 
48 months). All participants provided written informed con-
sent prior to entering the study, which has been approved by 
the local Ethical Committee and was in accordance with the 
Declaration of Helsinki.
Clinical assessment
All patients, at baseline and follow-up, underwent a standard 
neurological examination performed by neurologists expe-
rienced in Movement Disorders. Demographic, clinical and 
pharmacological data were collected from patients’ medical 
records. PD severity was evaluated with the Unified Parkin-
son Disease Rating Scale-Motor Evaluation (UPDRS-ME) 
and the Hoehn–Yahr (HY) scale. All motor evaluations have 
been conducted in “off” state. The clinical phenotype has 
been attributed according to the classification in Tremor 
Dominant (TD), Postural Instability Gait Difficulty (PIGD) 
and Undetermined using scores from part II and III of 
UPDRS [21].
Neuropsychological and behavioral assessment
At baseline and follow-up examinations, all PD subjects 
underwent a comprehensive neuropsychological and behav-
ioral assessment in “on” state. The following five cognitive 
domains were evaluated with two tests for domain: episodic 
memory (Rey’s Auditory Verbal Learning Test and Prose 
recall test with a delayed recall condition); attention (Stroop 
color-word test and Trail Making Test part A); executive 
functioning (Verbal fluency letter test and Colored Raven’s 
Progressive Matrices); visuo-spatial functioning (Clock 
drawing test and Copy of figures); language (Aachener 
Aphasie Test-Naming item and the short version of the 
Token test). Neuropsychological tests were considered as 
“impaired” when the subject scored two standard deviation 
(SD) below normality cut-off values. Diagnosis of PD-MCI 
was made according to the Movement Disorder Society Task 
Force criteria-level II [10]. Diagnosis of PDD was made 
according to the MDS criteria [11]. Details about the neu-
ropsychological assessment used in the PACOS have been 
extensively reported elsewhere [8, 9].
Assessment of VRFs
Vascular risk factors, comorbidities and medications were 
evaluated at baseline. Data have been recorded from clinical 
record of patients. Vascular comorbidities included history 
of diabetes, hypertension and the use of anti-hypertensive 
drugs, hypercholesterolemia and hypertriglyceridemia. His-
tory of myocardial infarction, coronary artery bypass graft, 
angioplasty or stenting, atrial fibrillation, or valvulopathy 
determined a diagnosis of heart disease. History of TIA or 
stroke as well as tobacco use, has been also collected. Serum 
lipids (LDL/HDL/total cholesterol), triglycerides and gly-
caemia have been extracted from clinical records. Systolic 
and diastolic pressures have been recorded from the cardio-
logic examination during patient admission and as the result 
of three different measurements three minutes apart.
To assess the role of VRFs on cognition, patients were clas-
sified according to the simplified 10-year Framingham General 
Cardiovascular Disease Risk Score [22]. The ratio between 
individual FR score and normative risk score has been used 
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to classify patients in High Vascular Risk (HVR; ratio > 1.0) 
and Low Vascular Risk (LVR; ratio ≤ 1.0) [13].
White matter lesions assessment
Patients underwent 1.5 T MRI scan (Signa HDxt, GE Medi-
cal Systems, Milwaukee, WI, USA) ± 1 month the baseline 
neuropsychological evaluation.
WMLs were defined as areas of hyperintensities on either 
T2 or FLAIR images, using a validated semiquantitative 
method proposed by Wahlund et coll [23]. Two blinded neu-
rologists have independently evaluated the findings on MRI 
images.
Statistical analysis
Data were analyzed using STATA 12.1 software packages 
(StataCorp, College Station, TX, USA). Quantitative vari-
ables were described using mean and standard deviation. The 
difference between means and proportions was evaluated by 
the t-test and the Chi square test, respectively. In case of a 
not normal distribution, appropriate non-parametric tests were 
performed.
For incident PDD cases, we assigned time of dementia 
onset to the midpoint of the interval between assessments at 
which dementia was diagnosed. Because PD-MCI, in contrast 
to PDD, may be reversible or fluctuate over time, we set time 
of onset of incident PD-MCI to the exact date at which PD-
MCI was first diagnosed. To identify possible predictors of 
progression from NC to MCI or PDD among the clinical and 
demographic characteristics, Cox proportional-hazards regres-
sion model was used for both the univariate and multivariate 
analyses. Variables with p value < 0.1 at univariate analysis 
were included in the final multivariate Cox models. Age, sex, 
UPDRS-ME and education were considered a priori confound-
ers and included in the model regardless the significance level. 
Schoenfeld residuals test was used for testing the proportional 
hazard. 95% confidence interval (CI), and p value (two-tailed 
test, a = 0.05).
Whenever variables were dichotomized or polychotomized, 
the cut-offs were derived from the pooled distribution of cases 
and control subjects (e.g., using the median value). Levodopa 
equivalent daily dose (LED) was calculated [24].
The Wahlund score was considered as the total score (range 
0–30) and was also polychotomized into three levels according 
to the pooled distribution (level 0 = absence of lesions; level 
1 when the total score was between 1 and 4; level 2 when the 
total score was > 4).
Results
The PACOS cohort consists of 659 non-demented PD 
patients [8]. Of the 659 subjects, 139 PD patients (men 
87, 62.6%) with a mean disease duration of 3.0–2.8 years 
who underwent at least two neuropsychological evalua-
tions between 12 and 48 months from 2014 to 2017 were 
enrolled in the present study. When compared to the base-
line cohort, patients enrolled in this study were compara-
ble in terms of demographic and clinical characteristics, 
except for a slightly shorter disease duration [9].
Of the 139 patients at baseline (first neuropsychological 
evaluation), 84 (60.4%) were classified as PD with normal 
cognition (PD-NC), while 55 (39.6%) fulfilled the diag-
nosis of PD-MCI. Baseline characteristics are reported in 
Table 1.
Considering the whole sample of 139 enrolled PD 
patients, patients with a diagnosis of MCI at baseline were 
more likely to have reported a history of diabetes, hyper-
tension, use of anti-hypertensive drugs and had a higher 
baseline both systolic (SBP) and diastolic blood pressure 
(DBP) as shown in Table 2.
At baseline according to the FR score, 39 patients (28.1%) 
were classified as LVR, while 100 (71.9%) as HVR. HVR 
was more frequent among the 55 PD-MCI at baseline with 
respect to the PD-NC (76.4% versus 69.0%), but such differ-
ence was not statistically significant (p value 0.3).
Vascular risk factors and risk of PD‑MCI
Considering the 84 PD-NC at baseline, 28 (33.3%) ful-
filled the diagnosis of PD-MCI, while 4 (4.8%) fulfilled 
the diagnosis of PDD at follow-up (mean follow-up time 
23.5 ± 10.3 months) as displayed in Fig. 1.
At univariate analysis age at baseline and use of antihy-
pertensive drugs were positively associated with the risk 
of MCI. As previously reported, education was negatively 
associated with the development of MCI [8, 9].
Considering the presence of hypertension, at univari-
ate analysis, we found a positive association for history 
of hypertension with a trend towards significant. Fur-
thermore, an association with a trend towards significant 
was also found for the presence of a SBP > 130 mmHg 
(median value of the pooled distribution), as well as with 
SBP > 140 mmHg, dichotomized according to the current 
definition of hypertension [25]. The presence of a Wahlund 
score greater than four was associated with the risk of MCI 
with a trend towards significance, as shown in Table 3.
On the other hand, diabetes, hypercholesterolemia, 
hypertriglyceridemia, atrial fibrillation, TIA or stroke as 
well as FR score were not associated with the risk of MCI.
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At multivariate analysis, adjusting by age, sex, educa-
tion and UPDRS-ME, we found an association with a trend 
towards significance between the use of antihypertensive 
drug and the risk of MCI (HR 2.32; 95% CI 0.95–5.66; p 
value 0.06). However, when the multivariate model was 
built considering the presence of a SBP > 140 a four times 
increased risk of MCI was recorded (HR 4.04; 95% CI 
1.41–11.3; p value 0.009) as shown in Table 3. A close 
HR was found when the analysis was adjusted by the use 
of antihypertensive drugs (HR 3.37; 95% CI 1.48–8.91; p 
value 0.03). It should be noted that, a more than 3-times 
increased risk of MCI was also recorded also considering 
a SBP > 130 mmHg, adjusting by age, sex education and 
UPDRS-ME (HR 3.59, 95% CI 1.47–8.74; p value 0.005). 
DBP was not associated with PD-MCI either at univariate 
or multivariate analysis and did not modify the strength of 
association of SBP. No significant association was found 
Table 1  Demographic and 
clinical characteristics at 
baseline
Data presented are number (percentage %) for categorical and mean ± SD for continuous data. Significant 
results are expressed in bold
NC normal cognition, MCI mild cognitive impairment, UPDRS-ME Unified Parkinson’s Disease Rating 
Scale-Motor Examination, HY Hoeh-Yahr, LED levodopa equivalent daily dose, TD tremor dominant, 
PIGD postural instability gait difficulty
NC (N = 84) MCI (N = 55) Total (N = 139) p value
Men 52 (61.9) 35 (63.6) 87 (62.6) 0.8
Age, years 64.4 ± 10.4 67.5 ± 7.4 65.7 ± 9.4 0.07
Age at onset, years 61.6 ± 11.0 64.5 ± 7.8 62.8 ± 10.0 0.09
Education, years 9.3 ± 4.4 8.3 ± 4.6 8.9 ± 4.6 0.2
UPDRS-ME score 25.4 ± 14.5 27.4 ± 11.9 26.2 ± 13.5 0.4
HY stage 1.9 ± 0.6 2.2 ± 0.7 2.0 ± 0.7 0.02
Disease duration, y 3.0 ± 2.9 3.0 ± 2.7 3.0 ± 2.8 0.9
Depression 29 (34.5) 22 (40.0) 51 (36.7) 0.4
LED mg/day 437.2 ± 463.8 397.9 ± 408.8 421.8 ± 442.0 0.6
Phenotype
 TD 32 (38.1) 11 (20.0) 43 (30.9) /
 PIGD 47 (55.9) 39 (70.9) 86 (61.9) /
 Mixed 5 (5.9) 5 (9.1) 10 (7.2) 0.07
Table 2  Vascular risk factors at baseline
Data presented are number (percentage %) for categorical and mean 
± SD for continuous data. Significant results are expressed in bold
NC normal cognition, MCI mild cognitive impairment, H history, 
SBP systolic blood pressure, DBP diastolic blood pressure, HDL high 
density lipoproteins, FR score HVR Framingam Risk Score, high vas-
cular risk, TIA transient ischemic attack
a Number of cigarette/day was available for 126 subjects
Vascular risk factors NC (N = 84) MCI (N = 55) p value
Diabetes (H) 10 (12.2) 16 (29.1) 0.01
Hypercholesterolemia (H) 26 (31.7) 20 (36.3) 0.50
Hypertension (H) 46 (56.1%) 40 (72.73) 0.03
Hypertrigliceridemia (H) 9 (11.0) 11 (20.0) 0.12
SBP mmHg 127.5 ± 8.3 133.8 ± 16.9 0.01
DBP mmHg 76.0 ± 7.2 80.4 ± 10.0 0.01
SBP > 130 (median value) 30 (35.7) 27 (49.1) 0.1
SBP > 140 12 (14.3) 13 (23.6) 0.2
Antihypertensive drugs 44 (52.4) 39 (70.9) 0.03
HDL mg/dl 48.0 ± 11.8 49.5 ± 9.7 0.41
Total cholesterol mg/dl 180.2 ± 36.1 177.4 ± 32.7 0.6
Smoking 15 (19.7) 11 (20.3) 0.3
 Cigarette/diea 17.8 ± 11.7 16.6 ± 13.4 0.99
Atrial fibrillation 1 (1.2) 3(5.4) 0.1
FR Score (HVR) 58(69.0) 42 (75.4) 0.3
Myocardial infarction 9 (11.0) 6 (10.9) 0.9
Stroke 0 1(1.8) /
TIA 0 0 /
Average Wahlund 2.2 ± 2.8 3.3 ± 4.5 0.07
Wahlund score
 0 (score = 0) 39 (46.4) 26 (47.3)
 1 (score 1–4) 34(40.2) 9 (16.4)
 2 (score > 4) 11 (13.1) 20 (36.4)
Fig. 1  Flowchart of the evolution of PD-NC and PD-MCI from base-
line to follow-up. PD Parkinson’s disease, NC normal cognition, PDD 
Parkinson’s disease dementia
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Table 3  Development of PD-MCI considering the 84 PD-NC at baseline. Cox proportional-hazards regression models
MCI N = 28 No-MCI 
N = 52
Univariate analysis Multivariate analysis
HR 95% CI p value HR 95% CI p value
Men 18 (64.3) 33 (63.4) 1.30 0.58–2.90 0.6 0.66 0.25–1.70 0.4
Age, years 68.5 ± 9.8 62.2 ± 10.3 1.04 1.00–1.09 0.04 1.63 0.99–1.10 0.1
Age at onset, 
years
65.2 ± 10.8 59.6 ± 11.0 1.04 1.00–1.08 0.06
UPDRS-ME 24.4 ± 13.0 24.6 ± 14.2 0.98 0.95–1.00 0.2 0.97 0.94–1..00 0.05
HY stage 2.1 ± 0.9 1.9 ± 0.5 1.21 0.76–1.94 0.4
Disease dura-
tion, y
3.3 ± 3.1 2.6 ± 2.7 1.01 0.90–1.14 0.8
Education, 
years
7.5 ± 4.8 10.5 ± 4.1 0.90 0.82–0.98 0.02 0.90 0.82–0.98 0.02
 Educa-
tion ≤ 8
21 (75.0) 22 (42.3) 1 / /
 Educa-
tion > 8
7 (25.0) 30 (57.7) 0.35 0.15–0.82 0.02
LED mg/day 480.8 ± 569.5 425.0 ± 415.6 1.00 0.99–1.00 0.5
Depression 13 (46.4) 45 (31.8) 1.80 0.83–3.88 0.1
Phenotype
 TD 11 (39.3) 19 (42.2) 1
 PIGD 15 (53.6) 24 (53.3) 0.75 0.34–1.65 0.5
 Mixed 2 (7.1) 2 (4.4) 3.50 0.72–16.9 0.1
Smoking 4 (36.4) 11 (18.9) 0.78 0.27–2.32 0.7




7 (25.0) 17 (32.7) 0.65 0.28–1.54 0.3
Hypertension 
(H)




19 (67.8) 24 (46.1) 1.53 0.61- 3.81 0.4
SBP, mmHg 132.1 ± 12.2 125.5 ± 13 1.02 0.99 -1.05 0.2
DBP, mmHg 77.6 ± 8.2 75.2 ± 6.5 1.01 0.97- 1.06 0.6
SBP > 130 
(median 
value)
14 (50.0) 14 (26.9) 1.93 0.92- 4.05 0.08
SBP > 140 7 (25.0) 4 (7.7) 1.78 0.75–4.21 0.1 4.04 1.41–11.3 0.009
Antihyperten-
sive drugs
20 21 2.85 1.25- 6.52 0.01
HDL, mg/dl 50.0 ± 13.4 46.2 ± 10.0 1.01 0.98- 1.04 0.4
Total choles-
terol, md/dl
175.2 ± 31.8 180.6 ± 38.3 1.00 0.99–1.01 0.9
Atrial Fibril-
lation






3 (10.7) 6 (11.5) 0.57 0.17- 1.90 0.4
Stroke 0 0 / / /
TIA 0 0 / / /
Average 
Wahlund
1.7 ± 2.3 3.0 ± 3.5 1.07 0.96–1.20 0.2
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at multivariate analysis between presence of WMLs and 
risk of MCI. Multivariate analysis is reported in Table 3.
Vascular risk factors and risk of PDD
Considering the entire sample of 139 PD patients, 18 ful-
filled the diagnosis of PDD at follow-up (mean follow-up 
time 24.0 ± 10.2 months) (Fig. 1). At univariate analysis age 
at baseline and education were significantly associated with 
the risk of developing dementia. Presence of MCI at base-
line was the strongest predictor of PDD (HR 4.37; 95% CI 
1.42–13.5, p value 0.01) along with the presence of WMLs 
at baseline (Wahlund score > 4 h 3.81, 95% CI 1.28–11.3; 
p value 0.01). None of the vascular risk factors evaluated 
were associated with the development of PDD including the 
FR score. At multivariate analysis, adjusting by age, sex, 
education and UPDRS-ME, the presence of MCI remained 
the strongest predictor of PDD (HR 7.55; 95% CI 1.76–32.3; 
p value 0.006) along with male sex (HR 4.94; 95% CI 
1.23–18.80; p value 0.02). Presence of WMLs increased the 
risk of PDD of almost 3-times, with an association with a 
trend towards significance (Wahlund score > 4 h 2.80; 95% 
CI 0.86–9.04; p value 0.08) (Table 4).
However, it should be noted that when Wahlund score 
was included in the model as continuous variable the asso-
ciation was significant (HR 1.15; 95% CI 1.01–1.31; p value 
0.02) and a close HR was found for MCI at baseline (HR 
6.62; 95% CI 1.87–23.5; p value 0.003) and male sex (HR 
5.00; 95% CI 1.34–18.62; p value 0.02).
Discussion
The specific contribution of vascular pathology in PD 
cognitive dysfunction is still debated. Several studies that 
have evaluated the possible role of VRFs and WMLs were 
performed before the new PD-MCI criteria and, for the dif-
ferent definitions adopted, results are scarcely comparable 
[26, 27].
To date, few cross-sectional [7, 12, 13] and longitudinal 
studies [14–16] have evaluated the role of both VRFs and 
WMLs in the risk of developing cognitive decline in PD 
patients using the new MDS criteria but conflicting results 
have been reported also by these more recent studies. In 
particular, different study design (cross-sectional versus lon-
gitudinal), different levels of PD-MCI MDS criteria (level 
I versus level II), different measures or definition of VRFs 
(Framingham Index rather than singular VRFs; self-reported 
history versus instrumental evaluation of VRFs), different 
estimation of WMLs (visual versus automatic) as well as 
the different MRI equipment can largely affect the results.
VRFs and WMLs and risk of PD‑MCI
Out of the 84 PD-NC at baseline, 33.3% developed MCI 
at follow-up. As already reported elsewhere, older age and 
low education level have been significantly associated with 
the risk of MCI occurrence [9]. Considering the VRFs in 
the present study, hypertension was the most important 
predictor of MCI at multivariate analysis. In particular, 
a 4-times increased risk of PD-MCI has been recorded 
among patients with SBP > 140  mmHg and a 3-times 
increased risk has been also recorded for PD patients 
with SBP > 130 mmHg. A similar result was found when 
antihypertensive drugs were used as surrogate marker for 
hypertension, thus confirming its role regardless the dif-
ferent types of measurement. This finding is in agreement 
with the longitudinal study carried out by Park et al. were 
hypertension was strongly associated with the conversion 
from PD-NC to PD-MCI [16]. Also in the cross-sectional 
study carried out by Pilotto et al. hypertension was signifi-
cantly more frequent in PD-MCI and dementia subgroups, 
Data presented are number (percentage %) for categorical and mean ± SD for continuous data. Significant results are expressed in bold
MCI mild cognitive impairment, NC normal cognition, HR hazard ratio, UPDRS-ME Unified Parkinson’s Disease Rating Scale-Motor Examina-
tion, HY Hoeh-Yahr, LED levodopa equivalent daily dose, TD tremor dominant, PIGD postural instability gait difficulty, H history, SBP systolic 
blood pressure, DBP diastolic blood pressure, HDL high density lipoproteins, FR score HVR Framingam Risk Score, high vascular risk, TIA 
transient ischemic attack
Table 3  (continued)
MCI N = 28 No-MCI 
N = 52
Univariate analysis Multivariate analysis
HR 95% CI p value HR 95% CI p value
Wahlund 
score
 0 (score = 0) 13 (46.4) 25 (48.1) 1 / /
 1 (score 
1–4)
7 (25) 24 (46.1) 0.79 0.31–1.98 0.6
 2 ( 
score > 4)
8 (28.6) 3 (5.8) 2.17 0.89–5.29 0.09
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even if this association was not significant at multivariate 
analysis [12]. However, neither the cross-sectional study 
carried out by Malek et al. [7] nor the longitudinal one 
performed by Sunwoo et al. [15] reported an association 
between hypertension and PD-MCI. In some studies, the 
possible role of VRFs was evaluated only considering the 
FR score [13, 14]. We did not find any association between 
FR score and PD-MCI and this result is agreement with 
Table 4  Development of PDD. Cox proportional-hazards regression models
Data presented are number (percentage %) for categorical and mean ± SD for continuous data. Significant results are expressed in bold
PDD Parkinson’s disease dementia, HR hazard ratio, UPDRS-ME Unified Parkinson’s Disease Rating Scale Motor Examination, HY Hoeh-Yahr, 
LED levodopa equivalent daily dose, NC normal cognition, MCI mild cognitive impairment, TD Tremor Dominant, PIGD postural instability 
gait difficulty, H history, SBP systolic blood pressure, DBP diastolic blood pressure, HDL high density lipoproteins, FR score HVR Framingam 
Risk Score, high vascular risk, TIA transient ischemic attack
PDD N = 18 No-PDD N = 121 Univariate analysis Multivariate analysis
HR 95% CI p value HR 95% CI p value
Men 12 (66.7) 75 (62.0) 1.21 0.44–3.37 0.7 4.94 1.23–18.8 0.02
Age, years 68.3 ± 8.4 65.3 ± 9.5 1.07 1.00–1.15 0.04 1.05 1.00–1.14 0.2
Age at onset, years 64.9 ± 8.4 62.4 ± 10.1 1.05 0.99–1.12 0.1
UPDRS-ME 33.1 ± 16.5 25.1 ± 12.7 1.03 1.00–1.05 0.06 1.03 1.00–1.07 0.05
HY stage 1.9 ± 0.6 2.1 ± 0.7 0.77 0.40–1.47 0.4
Disease duration, years 3.4 ± 2.8 2.9 ± 2.8 1.07 0.92–1.25 0.3
Education, years 7.4 ± 4.8 9.2 ± 4.5 0.88 0.78–0.99 0.04 0.83 1.29–18.7 0.03
LED mg/day 353.8 ± 298.4 432.1 ± 459.8 1.00 1.00–1.001 0.9
Cognition baseline
 NC 4 (22.2) 80 (66.1) 1 / /
 MCI 14 (77.8) 41 (33.9) 4.37 1.42–13.5 0.01 7.55 1.76–32.3 0.006
Depression 9 (50.0) 42 (34.7) 1.28 0.50–3.24 0.6
Phenotype
 TD 6 (33.3) 37 (30.6) 1 / /
 PIGD 12 (66.7) 74 (61.2) 1.01 0.38–2.76 0.9
 Mixed 0 10 (8.3) / / /
Smoking 2 (12.5) 24 (21.0) 0.52 0.11–2.36 0.4
Diabetes (H) 3 (16.7) 23 (19.0) 0.75 0.21–2.68 0.7
Hypercholesterolemia (H) 5 (27.8) 41 (33.9) 0.66 0.23–1.88 0.4
Hypertension (H) 14 (77.8) 72 (59.5) 2.09 0.68–6.44 0.2
Hypertrigliceridemia (H) 2 (11.1) 18 (14.9) 0.75 0.16–3.30 0.7
SBP, mmHg 129.2 ± 19.0 130.1 ± 14.8 1.00 0.97–1.03 0.9
DBP, mmHg 80 ± 11.5 77.4 ± 8.2 1.03 0.99–1.09 0.1
SBP > 130 (median value) 10 (55.6) 47 (38.8) 1.89 0.70–5.02 0.2
SBP > 140 4 (22.2) 21 (17.4) 1.17 0.38–3.61 0.8
Antihypertensive drugs 14 (77.8) 69 (57.0) 2,30 0.74–7.05 0.1
HDL, mg/dl 48.4 ± 12.4 48.6 ± 10.8 0.99 0.94–1.03 0.7
Total cholesterol, mg/dl 182 ± 38.0 178.7 ± 34.4 1.00 0.99–1.01 0.6
Atrial Fibrillation 1 (5.6) 3 (2.5) 2.24 0.29–17.2 0.4
FR Score (HVR) 14 (77.8) 86 (71.1) 1.24 0.40–3.81 0.7
Myocardial Infarction 1 (5.6) 14 (11.6) 0.44 0.05–3.38 0.4
Stroke / 1 (0.8) / / /
TIA / / / / /
Average Wahlund 4.3 ± 4.3 2.4 ± 3.3 1.16 1.04–1.30 0.007
Wahlund score
 0 (score = 0) 6 (33.3) 59 (48.8) 1 / / 1 / /
 1 (score 1–4) 4 (22.2) 39 (32.2) 0.71 0.16–3.02 0.6 2.31 0.47–11.2 0.3
 2 (score > 4) 8(44.4) 23 (19.0) 3.81 1.28–11.3 0.01 2.80 0.86–9.04 0.08
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the Parkinson’s Progression Markers Initiative study [14]. 
Contrarily, in the cross-sectional study recently carried out 
by Stojkovic and coll, the FR score was associated with 
PD-MCI [13].
Concerning WMLs, we found an association with a trend 
towards significance with a Wahlund score greater than 4 
(HR 2.17; p value 0.09) and PD-MCI. This finding is in 
agreement with the longitudinal studies carried out by Cha-
hine et al. [14] and by Sunwoo et al. [15] Similarly, Stojkovic 
et al. reported an association between WMLs and PD-MCI 
with a trend towards significance [13]. However it should 
be noted that in the study carried out by Park et al. [16] the 
presence of severe cerebral small vessel disease in the basal 
ganglia was found to be strongly associated with PD-MCI.
In our study we did not find any association between 
tobacco smoking and occurrence of neither PD-MCI nor 
PDD. In the general population, the role of nicotine in favor-
ing or preventing cognitive decline is still controversial. In 
particular, if on the one hand nicotine increase oxidative 
stress-related cerebrovascular damage, favoring cognitive 
decline, on the other hand it could counterbalance cholin-
ergic deficits preventing dementia.[27]. However, a recent 
meta-analysis of prospective cohort study, reported that 
tobacco smoking increased the risk of cognitive decline in 
PD [28].
VRFs and WMLs and the risk of PDD
Considering the 139 non-demented patients at baseline, 
12.9% developed PDD at follow-up. As reported elsewhere, 
MCI was the stronger predictor of PDD along with male sex 
while education was protective [9].
Along with these recognized risk factors, PDD was 
strongly predicted by the WMLs burden at baseline. At 
multivariate analysis, an almost 3-time risk was found for a 
Wahlund score > 4 even if such association was with a trend 
towards significance (HR 2.80; p value 0.08). Nonetheless, 
it should be noted that the association became significant 
when Wahlund score was included in the model as contin-
uous variable (HR 1.15; p value 0.02). This finding is in 
agreement with the studies carried out by Stojkovic, Sunwoo 
and Park [13, 15, 16] which showed that the presence of 
WMLs was not associated with PD-MCI but only with PDD. 
Conversely, none of the VRFs evaluated was significantly 
associated with PDD.
Hypertension is a recognized risk factor for cognitive 
decline in PD [29–32]. However, in the present study, the 
presence of hypertension at baseline was only associated 
with the development of MCI and not of PDD, the latter 
associated only with the WMLs burden.
MCI is present in about 30% of incident PD patients and 
represents the most important risk factors for the develop-
ment of PDD [8, 9]. Hypertension, especially if uncontrolled, 
is a major risk factor for the development of WMLs, leading 
to vascular cognitive impairment [31]. Hypertension, in fact, 
leads to structural changes of cerebral vessels as adaptive 
consequence to counteract the increased transmural pressure. 
However, over the time, these structural changes predispose 
to different pathologies, including microatheroma, micro-
infarcts, microbleeds, lacunae, atherosclerosis, resulting in 
WMLs [33]. Moreover, it has been reported that patients suf-
fering from hypertension, frequently experience orthostatic 
hypotension, the latter in turn associated with both cognitive 
decline [34, 35] and cerebral hypoperfusion [36].
Hence, it could be hypothesized that, in an early stage 
hypertension but not WMLs, increases the risk of MCI. 
Subsequently, while the neuropathological vascular dam-
age driven by hypertension prosecutes, the development of 
WMLs, an irreversible factor, contributes to PDD occur-
rence. Thus, the maintenance of an appropriate blood pres-
sure control, could represent a feasible strategy to reduce 
MCI, WMLs and, finally, PDD occurrence.
Our study has several strengths, including the large 
PACOS cohort size at baseline [8], the application of MDS 
Level II diagnostic criteria for PD-MCI diagnosis and the 
assessment of VRFs with different sources to evaluate the 
presence of different exposures (e.g. self-reported history 
of hypertension, use of antihypertensive drugs and blood 
pressure measurement; self-reported history of hypercholes-
terolemia, serum lipid levels, etc.). To the best of our knowl-
edge, this is the largest longitudinal study which simulta-
neously assessed the combined role of several VRFs and 
WMLs in subjects fulfilling the MDS Level II requirements 
for PD-MCI conducted to date.
Nonetheless, several limits should be considered in inter-
preting our data. First, a possible selection bias cannot be 
excluded due to the hospital-based study design. As for other 
hospital-based cohorts, presence of more severe cases can-
not be excluded, and this may possibly have contributed to 
the high estimate of MCI at baseline. Nonetheless the aver-
age HY score and the short disease duration recorded in the 
PACOS cohort have revealed a mild to moderate stage of 
disease [8, 9]. Furthermore, although analyses were adjusted 
for major potential confounders, residual confounding can-
not be excluded. A further limit is related to the evaluation of 
the WMLs burden that was estimated with the visual score 
of Wahlund and not with a software package. However, it 
should be noted that the scoring was performed by two neu-
rologists blinded to clinical information of patients. Finally, 
probably due to the relatively small sample of PD-NC that 
develop PD-MCI at follow-up, we obtained wide CIs thus 
limiting the generalizability of our results.
In conclusion, results of the present report suggest that 
hypertension is the strongest vascular risk factor for the 
development of cognitive impairment in PD. Considering 
that hypertension is a modifiable risk factor, its control 
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might have a role in preventing PD-MCI and, consequently, 
PDD occurrence. Thus, this data have relevant prognostic 
and therapeutic implications. Larger prospective cohort stud-
ies, as well as blood pressure intervention trials are needed 
to confirm the role of hypertension as modifiable risk factor 
for cognitive impairment in PD.
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